Search research articles
Contact Us
Filters
Showing results (361-370 of 524) with videos related to
Page
of 53
Sort By:
Metabolites
|
January 21, 2023
The Role of Advanced Glycation End Products on Dyslipidemia
Jelena Vekic, Sanja Vujcic, Biljana Bufan, et al.
Current Pharmaceutical Design
|
January 3, 2013
A review of the cardiovascular and anti-atherogenic effects of ghrelin
Manfredi Rizzo, Ali A Rizvi, Emina Sudar, et al.
Current Atherosclerosis Reports
|
August 4, 2021
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
Arrigo F G Cicero, Federica Fogacci, Anca Pantea Stoian, et al.
The American Journal of Cardiology
|
February 12, 2002
Changes in plasma lipids and low-density lipoprotein peak particle size during and after acute myocardial infarction
Carlo M Barbagallo, Manfredi Rizzo, Angelo B Cefalu', et al.
Expert Opinion on Drug Safety
|
April 3, 2020
An overview of statin-induced myopathy and perspectives for the future
Dragana Nikolic, Maciej Banach, Roberta Chianetta, et al.
International Journal of Cardiology. Cardiovascular Risk and Prevention
|
December 30, 2024
Diabetic cardiomyopathy: pathophysiology, imaging assessment and therapeutical strategies
Vincenzo Rizza, Lara Tondi, Angelo Maria Patti, et al.
Medicina (Kaunas, Lithuania)
|
June 28, 2023
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Ioana-Cristina Bica, Roxana Adriana Stoica, Teodor Salmen, et al.
Diabetes Research and Clinical Practice
|
May 28, 2026
Repurposing GLP-1 receptor agonists and SGLT-2 inhibitors in neurodegeneration and metabolically at-risk populations: Myth or reality? An overview of randomized clinical trials
Michail-Angelos Mourtzos, Dimitrios Patoulias, Natalia-Maria Keklikoglou, et al.
Pharmaceutics
|
April 23, 2022
Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
Jelena Vekic, Aleksandra Zeljkovic, Aleksandra Stefanovic, et al.
Cardiovascular Diabetology
|
November 29, 2022
Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)
Maciej Banach, Stanisław Surma, Zeljko Reiner, et al.
Page
of 53
Search research articles
Search
Showing results (361-370 of 524) with videos related to
Sort By:
Page
of 53
Metabolites
|
January 21, 2023
The Role of Advanced Glycation End Products on Dyslipidemia
Jelena Vekic, Sanja Vujcic, Biljana Bufan, et al.
Current Pharmaceutical Design
|
January 3, 2013
A review of the cardiovascular and anti-atherogenic effects of ghrelin
Manfredi Rizzo, Ali A Rizvi, Emina Sudar, et al.
Current Atherosclerosis Reports
|
August 4, 2021
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
Arrigo F G Cicero, Federica Fogacci, Anca Pantea Stoian, et al.
The American Journal of Cardiology
|
February 12, 2002
Changes in plasma lipids and low-density lipoprotein peak particle size during and after acute myocardial infarction
Carlo M Barbagallo, Manfredi Rizzo, Angelo B Cefalu', et al.
Expert Opinion on Drug Safety
|
April 3, 2020
An overview of statin-induced myopathy and perspectives for the future
Dragana Nikolic, Maciej Banach, Roberta Chianetta, et al.
International Journal of Cardiology. Cardiovascular Risk and Prevention
|
December 30, 2024
Diabetic cardiomyopathy: pathophysiology, imaging assessment and therapeutical strategies
Vincenzo Rizza, Lara Tondi, Angelo Maria Patti, et al.
Medicina (Kaunas, Lithuania)
|
June 28, 2023
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Ioana-Cristina Bica, Roxana Adriana Stoica, Teodor Salmen, et al.
Diabetes Research and Clinical Practice
|
May 28, 2026
Repurposing GLP-1 receptor agonists and SGLT-2 inhibitors in neurodegeneration and metabolically at-risk populations: Myth or reality? An overview of randomized clinical trials
Michail-Angelos Mourtzos, Dimitrios Patoulias, Natalia-Maria Keklikoglou, et al.
Pharmaceutics
|
April 23, 2022
Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
Jelena Vekic, Aleksandra Zeljkovic, Aleksandra Stefanovic, et al.
Cardiovascular Diabetology
|
November 29, 2022
Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)
Maciej Banach, Stanisław Surma, Zeljko Reiner, et al.
Page
of 53